Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26659630 | 0.93 | KCNA5 (0.50) | KCNA5ALDH1A1LMNAHIF1AKDM4A | |
| SCHEMBL6289403 | 0.87 | KCNA5 (0.49) | KCNA5ALDH1A1LMNAKDM4AATR | |
| SCHEMBL2381485 | 0.87 | KCNA5 (0.49) | KCNA5ALDH1A1LMNAHIF1AKDM4A | |
| SCHEMBL1808874 | 0.87 | KCNA5 (0.56) | KCNA5HIF1AKDM4AHPGDNAMPT | |
| SCHEMBL25762436 | 0.87 | KCNA5 (0.56) | KCNA5LMNAKDM4AHPGDNAMPT | |
| SCHEMBL31126851 | 0.86 | ALDH1A1 (0.57) | KCNA5ALDH1A1LMNAHIF1AHPGD | |
| SCHEMBL8018113 | 0.86 | KCNA5 (0.56) | KCNA5LMNAKDM4ANAMPTHDAC10 | |
| SCHEMBL30159605 | 0.86 | KCNA5 (0.56) | KCNA5LMNAKDM4ANAMPTHDAC10 | |
| SCHEMBL166559 | 0.86 | LMNA (0.55) | KCNA5ALDH1A1LMNATSHRNAMPT | |
| SCHEMBL8226733 | 0.86 | KCNA5 (0.53) | KCNA5ALDH1A1LMNAKDM4AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| EP-4229062-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022081758-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220119395-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-0920413-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND COMPLEXES | PROLINX, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0915832-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5877297-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872224-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859210-A | Boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5744627-A | Boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998005629-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KCNA5 1873/4885ALDH1A1 543/4885LMNA 1338/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | KCNA5 4700/4885ALDH1A1 1718/4885LMNA 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.